Search Results
Your search for ,iII matches 9383 pages
Showing 8601 - 8650SABCS 2015: No Significant Difference in Recurrence Rates Among Women With Ductal Carcinoma in Situ Taking Anastrozole or Tamoxifen
Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for 5 years after surgery, but women in the two groups had different side effects, according to results from the phase III...
SABCS 2015: Patients With Ductal Carcinoma in Situ Receiving Anastrozole Reported Symptoms Different From Those in Patients Receiving Tamoxifen
Analysis of patient-reported outcomes, a secondary endpoint of the phase III NSABP B-35 clinical trial, in which anastrozole and tamoxifen were compared in postmenopausal women with ductal carcinoma in situ (DCIS) who underwent lumpectomy plus radiotherapy, found that there were no differences in...
SABCS 2015: Pathologic Complete Response to Presurgery Chemotherapy Improves Survival for Patients With Triple-Negative Breast Cancer
Patients with stage II or stage III triple-negative breast cancer who had a pathologic complete response (pCR) after presurgery chemotherapy had increased event-free and overall survival compared with those who had more than minimal residual invasive disease at surgery following presurgery...
SABCS 2015: Women With Luminal A Breast Cancer Did Not Benefit From Adjuvant Chemotherapy in Phase III Trial
Premenopausal women whose invasive breast cancers were of the luminal A subtype had comparable 10-year disease-free survival rates, regardless of whether or not they received adjuvant chemotherapy, according to data from the phase III Dutch Breast Cancer Cooperative Group (DBCG77B) clinical trial...
SABCS 2015: Capecitabine Improved Outcomes for Breast Cancer Patients With Residual Disease After Presurgery Chemotherapy
Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer...
SABCS 2015: Denosumab Improves Disease-Free Survival for Postmenopausal Patients With Hormone Receptor–Positive Breast Cancer
Adding denosumab (Xgeva) to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor–positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast...
Improved Overall Survival With Addition of Nanoliposomal Irinotecan to Fluorouracil/Leucovorin in Metastatic Pancreatic Cancer
In the phase III NAPOLI-1 trial reported in The Lancet, Wang-Gillam et al found that the addition of nanoliposomal irinotecan (Onivyde) to fluorouracil (5-FU) and folinic acid (leucovorin) resulted in improved overall survival in patients with metastatic pancreatic ductal cancer who had received...
ASH 2015: Updated Results of Phase III Tourmaline-MM1 Study of Ixazomib in Multiple Myeloma
In a study presented by Moureau et al at the 57th American Society of Hematology (ASH) Annual Meeting, ixazomib (Ninlaro), a recently approved oral proteasome inhibitor, significantly extended progression-free survival for patients with relapsed and/or refractory multiple myeloma (Abstract 727)....
European Trial Shows Front-Line Addition of Nintedanib to Standard Chemotherapy Improves Progression-Free Survival in Advanced Ovarian Cancer
In a European phase III trial (AGO-OVAR 12) reported in The Lancet Oncology, du Bois et al found that adding the antiangiogenic multikinase inhibitor nintedanib (Ofev) to carboplatin/paclitaxel improved progression-free survival in patients with newly diagnosed ovarian cancer. Gastrointestinal...
ASH 2015: Ibrutinib Data Underscore Promise of Targeted Therapies as First-Line Approach for Patients With Chronic Lymphocytic Leukemia
A presentation by Tedeschi et al at the 57th American Society of Hematology (ASH) Annual Meeting outlined results of the phase III RESONATE TM-2 study of ibrutinib (Imbruvica) vs chlorambucil (Leukeran) in patients aged 65 years and older with treatment-naive chronic lymphocytic leukemia/small...
ASH 2015: Combination Therapy With Idelalisib Improves Progression-Free Survival vs Bendamustine/Rituximab Alone in Relapsed/Refractory CLL
In a phase III study to be presented by Zelenetz et al at the 57th American Society of Hematology Annual Meeting, idelalisib (Zydelig) plus bendamustine (Treanda) and rituximab (Rituxan), or BR, proved superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)...
Better Invasive Disease–Free Survival With Epirubicin/Cyclophosphamide and Docetaxel vs Epirubicin/Docetaxel and Capecitabine in Breast Cancer
In a Spanish phase III trial (GEICAM/2003-10) reported in the Journal of Clinical Oncology, Martín et al found that invasive disease–free survival was improved with adjuvant epirubicin/cyclophosphamide (EC) followed by docetaxel (EC-T) vs epirubicin/docetaxel followed by capecitabine...
ASH 2015: Midostaurin Improves Survival in Patients With FLT3-Mutated Acute Myeloid Leukemia Aged 18–60
A study presented by Stone et al at the 57th American Society of Hematology (ASH) Annual Meeting described a phase III trial of the first targeted therapy for genetically defined subset of patients with acute myeloid leukemia and its improvement of their survival (Abstract 6). Acute myeloid...
Reduced Nonrelapse Mortality With Busulfan/Fludarabine vs Busulfan/Cyclophosphamide for Stem Cell Transplantation in Acute Myeloid Leukemia
In a phase III trial reported in The Lancet Oncology, Rambaldi et al found that a myeloablative conditioning regimen of busulfan/fludarabine was associated with reduced nonrelapse mortality vs busulfan/cyclophosphamide in patients with acute myeloid leukemia (AML) undergoing allogeneic...
Benefit of Maintenance Bevacizumab-Erlotinib vs Bevacizumab After Bevacizumab-Based Induction Therapy in Metastatic Colorectal Cancer
As reported by Tournigand et al in The Lancet Oncology, final analysis of the phase III GERCOR DREAM (OPTIMOX3) trial suggested a benefit of maintenance bevacizumab (Avastin)-erlotinib vs bevacizumab after bevacizumab-based induction therapy in patients with previously untreated metastatic...
Study Finds Better Outcome With Melphalan Plus ASCT vs Chemotherapy Plus Lenalidomide Consolidation in Multiple Myeloma
In a phase III trial reported in The Lancet Oncology, Gay et al found that progression-free survival was shorter with lenalidomide (Revlimid) plus chemotherapy vs high-dose melphalan plus autologous stem cell transplantation in transplant-eligible patients with multiple myeloma, with no significant ...
Prognostic Model for Survival in Advanced-Stage Mycosis Fungoides and Sézary Syndrome
As reported by Scarisbrick et al in the Journal of Clinical Oncology, a Cutaneous Lymphoma International Consortium study in a large population of patients with advanced-stage mycosis fungoides and Sézary syndrome has identified independent prognostic factors for overall survival that can be ...
FDA Approves Single-Agent Nivolumab for Previously Untreated BRAF Wild-Type Advanced Melanoma
The U.S. Food and Drug Administration (FDA) today approved the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) as a single agent for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. Clinical Trial Results The approval is based on data...
10-Year Results of MOSAIC Trial Show Continued Survival Benefit of Adjuvant FOLFOX4 in Stage III Colon Cancer
Ten-year results of the MOSAIC trial, reported in the Journal of Clinical Oncology by André et al show a continued overall survival benefit with adjuvant FOLFOX4 (fluorouracil [5-FU] leucovorin plus oxaliplatin) vs 5-FU/leucovorin in patients with stage III colon cancer and in the entire...
‘Substantial Number’ of Patients Requiring Palliative Radiotherapy for Stage IV NSCLC Are Overtreated
An analysis of data from 46,803 patients with stage IV non–small cell lung cancer (NSCLC) who received palliative chest radiation therapy found that 49% received radiotherapy for longer than 15 fractions and 28% received more than 25 fractions. This treatment pattern “is inconsistent...
Increasing Use of Preoperative Breast MRI Linked to Increased Postdiagnostic Imaging and Biopsy, Mastectomy, and Surgery Delay
In a Canadian population-based study reported in JAMA Oncology, Arnaout et al found that breast magnetic resonance imaging (MRI) is increasingly used in preoperative evaluation of women with breast cancer and that its use is associated with increased likelihood of confirmatory breast imaging,...
No Difference in Overall Survival, Poorer Relapse-Free Survival With Adjuvant Intermittent vs High-Dose Interferon Alfa-2b in Stage III Melanoma
The final analysis of a European Dermatologic Cooperative Oncology Group phase III trial, reported in the Journal of Clinical Oncology by Mohr et al, showed that adjuvant intermittent vs standard high-dose intravenous interferon alfa-2b was associated with no difference in overall survival but...
Dexamethasone Reduces Pain Flare After Palliative Radiotherapy for Bone Metastases
In a Canadian phase III trial reported in The Lancet Oncology, Chow et al found that prophylactic dexamethasone reduced the incidence of radiation-induced pain flare compared with placebo in patients receiving palliative radiotherapy for bone metastases. Study Details In this double-blind trial,...
Lenalidomide Plus Rituximab Appears Promising as First-Line Therapy for Mantle Cell Lymphoma
Mantle cell lymphoma, which is characterized by CD5-positive, CD23-negative follicular mantle B cells with t(11:14)(q13;q32) translocation and cyclin D1 overexpression, is generally incurable and associated with a median survival of between 4 and 5 years. Although front-line treatment for mantle...
Phase III Trials Fail to Show Noninferiority of Surgical Outcome for Laparoscopic vs Open Resection in Rectal Cancer
Two phase III trials, reported in JAMA by Fleshman et al and Stevenson et al, failed to show noninferiority of surgical outcome for laparoscopic vs open resection in patients with rectal cancer. ACOSOG Z6051 Trial In the American College of Surgeons Oncology Group (ACOSOG) Z6051 trial, reported...
No Significant Survival Improvement With Etirinotecan Pegol vs Physician’s Choice in Heavily Pretreated Advanced Breast Cancer
In the phase III BEACON trial reported in The Lancet Oncology, Perez et al found that etirinotecan pegol was not associated with a significant increase in overall survival compared with physician’s choice of treatment in women with locally recurrent or metastatic breast cancer previously...
Chemoradiotherapy Survival Benefit in Elderly Patients With Limited-Stage SCLC
In a population-based study reported in the Journal of Clinical Oncology, Corso et al found that chemoradiotherapy was associated with an overall survival benefit vs chemotherapy in elderly patients with limited-stage small cell lung cancer (SCLC). Study Details The study involved National Cancer ...
Reduced Relapse but No Quality-of-Life Benefit With ATRA/Arsenic Trioxide vs ATRA/Idarubicin in Acute Promyelocytic Leukemia
In a UK-based phase III trial (AML17) reported in The Lancet Oncology, Burnett et al found that a chemotherapy-free regimen of arsenic trioxide plus all-trans retinoic acid (ATRA) did not improve quality of life, the primary endpoint, vs ATRA plus idarubicin in patients with acute promyelocytic...
Telotristat Etiprate Shows Clinical Benefit in Treating Carcinoid Syndrome in Cancer Patients When Added to Standard of Care
Lexicon Pharmaceuticals, Inc's telotristat etiprate was shown to have clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by long-acting somatostatin analog therapy, the current standard of care, according to data from the phase III TELESTAR study presented...
FDA Approves Talimogene Laherparepvec for Unresectable Recurrent Melanoma
The U.S. Food and Drug Administration (FDA) has approved the biologics license application for talimogene laherparepvec (Imlygic), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma...
ASTRO 2015: The Addition of 24 Months of Daily Antiandrogen Therapy Improves Overall Survival Following Recurrence After a Radical Prostatectomy
Prostate cancer patients who face recurrence after radical prostatectomy have better overall survival rates with a combination of salvage radiation therapy and 24 months of antiandrogen therapy than with radiation therapy alone, according to research (Abstract LBA5) presented by Shipley et al on...
ASTRO 2015: A Shorter Radiation Therapy Schedule Can Be as Effective as a Conventional Schedule for Men With Low-Risk Prostate Cancer
Hypofractionated radiation therapy results in similar rates of cure and side effects compared to a longer treatment schedule for some men with low-risk prostate cancer, according to research (Abstract LBA6) presented by Lee et al October 19, 2015, at the American Society for Radiation Oncology...
ASTRO 2015: Pediatric Patients With Ependymoma Have Favorable Outcomes With Immediate Postsurgical Radiation Therapy
Outcomes for pediatric patients as young as 12 months old with ependymoma who are treated with immediate postoperative radiation therapy are favorable and consistent, based upon tumor surgical resection and tumor grade, according to research presented by Merchant et al (Abstract 1) on October...
ASTRO 2015: Hypofractionated Radiation Therapy May Be an Acceptable Treatment for Some Patients With Localized Prostate Cancer
Long-term patient-reported outcomes indicate that for some men with localized prostate cancer, hypofractionated intensity-modulated radiation therapy (IMRT) may be a reasonable treatment option and result in similar quality-of-life outcomes, compared to conventional radiation therapy, according to...
ASTRO 2015: Patients With Intermediate-Risk Meningiomas Who Receive Postoperative Radiotherapy Have a 96% 3-Year Progression-Free Survival
Patients with intermediate meningiomas treated with radiation therapy after surgery experienced a 96% 3-year progression-free survival rate and had minimal adverse events, according to research presented by Rogers et al October 21, 2015, at the American Society for Radiation Oncology’s...
ASTRO 2015: Involved-Field Irradiation for Locally Advanced Esophageal Cancer Reduces Toxicity Without Increasing Locoregional Lymph Node Recurrence
For patients with locally advanced esophageal cancer that has spread to the lymph nodes, radiation therapy that targets only the involved lymph node regions results in less toxicity without causing a statistically significant difference in locoregional lymph node recurrence, distant failure, and...
ASTRO 2015: Intensity-Modulated Radiotherapy Causes Less Inflammation Than 3D Conformal Radiotherapy in Lung Cancer Patients
Patients with stage III non–small cell lung cancer (NSCLC) who receive intensity-modulated radiation therapy (IMRT) have 44% fewer cases of severe pneumonitis and improved likelihood of completing consolidative chemotherapy after radiation, compared to patients who receive three-dimensional...
ASTRO 2015: Image-Guided Intensity-Modulated Radiation Therapy Reduces Bowel Side Effects in Cervical Cancer Patients
For cervical cancer patients undergoing postsurgical radiation therapy, image-guided intensity-modulated radiation therapy (IMRT) resulted in a 14% reduction in moderate-to-severe bowel side effects when compared to conventional three-dimensional conformal radiation therapy (3D CRT), according to...
Study Compares Maintenance Strategies After First-Line Oxaliplatin/Fluoropyrimidine/Bevacizumab in Patients With Metastatic Colorectal Cancer
In a German noninferiority phase III trial (AIO 0207) reported in The Lancet Oncology, Hegewisch-Becker et al found that maintenance treatment with bevacizumab (Avastin) was noninferior to a fluoropyrimidine plus bevacizumab in time to maintenance strategy failure following first-line treatment...
ASTRO 2015: Accelerated Partial-Breast Irradiation With Brachytherapy After Breast-Conserving Surgery Is as Effective as Whole-Breast Irradiation
For some early-stage breast cancer patients, accelerated partial-breast irradiation using multicatheter brachytherapy following breast-conserving surgery may be an excellent treatment option, as it has now been proven to be as effective as the current standard treatment—whole-breast...
Similar Pain Outcome With Ibandronate vs Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer
In a UK phase III noninferiority trial reported in the Journal of the National Cancer Institute, Hoskin et al found similar effects of single-dose ibandronate and single-dose radiotherapy on localized metastatic bone pain in patients with prostate cancer. Study Details In the open-label trial,...
Inotuzumab Ozogamicin Receives FDA Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia
Pfizer announced that the investigational antibody-drug conjugate inotuzumab ozogamicin received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for acute lymphoblastic leukemia (ALL). The Breakthrough Therapy designation was based on the results of the phase III...
Researchers Identify Dozens of Genetic Mutations Driving CLL and Their Evolution in Progression and Relapse
An analysis of whole-exome sequencing data from 538 patients with chronic lymphocytic leukemia (CLL), including 278 pretreatment samples collected from patients enrolled in a clinical trial, has identified 44 recurrently mutated genes and 11 recurrent somatic copy number variations. These findings...
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer
Results of the phase III AHT trial reported in the Journal of Clinical Oncology by Eeles et al suggest that adjuvant hormonal therapy may improve survival in women with epithelial ovarian cancer. The trial, started in 1990, was stopped early due to low recruitment. Study Details In the open-label ...
To Optimize Tamoxifen Use Among Premenopausal Women With Breast Cancer, Include Access to Fertility-Preservation Options
A multivariable analysis of clinical factors associated with tamoxifen use among premenopausal women with hormone receptor–positive breast cancer showed that fertility preservation was a significant factor and “the only predictor of both noninitiation and early cessation” of...
No Difference in Outcomes With Short-Course vs Longer-Course Radiotherapy in Elderly or Frail Patients With Newly Diagnosed Glioblastoma
In a noninferiority phase III trial reported in the Journal of Clinical Oncology, Roa et al found no difference in overall survival, progression-free survival, or quality of life between short-course and longer-course radiotherapy in elderly or frail patients with newly diagnosed glioblastoma...
Cardiovascular Prevention Trial Shows Reduction in Invasive Breast Cancer Risk With Mediterranean Diet Supplemented by Extra-Virgin Olive Oil
As reported in JAMA Internal Medicine by Toledo et al, a large Spanish primary prevention nutrition intervention trial in patients at high cardiovascular risk (PREDIMED) showed a large reduction in risk for invasive breast cancer among women 60 to 80 years of age who were randomly assigned to the...
ECC 2015: Combination of Dabrafenib and Trametinib Superior to Vemurafenib Alone in Advanced Melanoma: Results of the COMBI-v Trial
The latest results from a trial of a combination of two targeted therapies (dabrafenib [Tafinlar] and trametinib [Mekinist]) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with vemurafenib (Zelboraf) alone. Caroline...
Breast Tumor Genomic Characteristics Suggest More Aggressive Biology in African American vs White Women
In a study reported in the Journal of Clinical Oncology, Keenan et al found that African American women with breast cancer had greater intratumor genetic heterogeneity, a higher frequency of TP53 mutation, and higher risk for basal tumors compared with white women, with the characteristics...
ECC 2015: Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma: Results of the IMvigor 210 Study
At the 2015 European Cancer Congress in Vienna, Austria, early results were announced (Abstract 21LBA) from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy atezolizumab (anti–PD-L1; MPDL3280A) in people with locally advanced or metastatic urothelial...
